Clinical trial

the Impact of Statin on Cirrhotic Patients

NCT05563389

Name

Statin and iver cirrhosis

Description

The study aims to evaluate the impact of statin on hepatic decompensation.

Trial arms

Trial start

2022-06-15

Estimated PCD

2023-02-25

Trial end

2023-02-25

Status

Completed

Phase

Early phase I

Treatment

Atorvastatin 20mg

active arm

Arms:

statin

Other names:

atorvastatin

Placebo

placebo arm

Arms:

PLACEBO

Size

100

Primary endpoint

impact on decompensation

6 months

Eligibility criteria

Inclusion Criteria: * cirrhosis adult both sex Exclusion Criteria: * renal insufficiency

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}

Updated at

2024-04-03

1 organization

2 products

1 indication

Organization

Product

Indication

Product